OSI-906 (Linsitinib) 化学構造
分子量: 421.49

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare IGF-1R Inhibitors
    IGF-1R製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 OSI-906(Linsitinib)は、IGF-IRとIrの選択的な阻害剤で、IC50 がそれぞれ 35 nM と 75 nMです。
ターゲット IGF-1R InsR
IC50 35 nM 75 nM [1]
In vitro試験 OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-Fuk NIK1dYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEK4NFYh|ryP M{j3e3NCVkeHUh?=
KS-1 M4LBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TIUWlEPTB;MD6wN|g{PSEQvF2= Mm\NV2FPT0WU
TE-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm0SIVoUUN3ME2wMlA4QDJ{IN88US=> MlXJV2FPT0WU
EW-1 NEPt[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDoWo9KSzVyPUCuNFg2QDVizszN M2rDXHNCVkeHUh?=
HMV-II MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEi4OFYh|ryP NH3Pd25USU6JRWK=
COLO-205 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH2PGVVUUN3ME2wMlExPDV2IN88US=> M3;hXHNCVkeHUh?=
ES1 NGfCSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvGTWM2OD1yLkGwOlk3KM7:TR?= MmXlV2FPT0WU
GDM-1 NUPzRoZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml63TWM2OD1yLkGzOlczKM7:TR?= NV6zcG15W0GQR1XS
ML-2 NFSzPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHtTWM2OD1yLkG1PFk3KM7:TR?= MXfTRW5ITVJ?
Saos-2 NFrUcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMU[1NlYh|ryP M3LxN3NCVkeHUh?=
NCI-H1355 M3;pUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\NTWM2OD1yLkG4NVM2KM7:TR?= NGHidmdUSU6JRWK=
G-401 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjGTWM2OD1yLkG4NlMh|ryP NG\sTVdUSU6JRWK=
EW-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUi3O|ch|ryP NILUfopUSU6JRWK=
EW-7 NGfEWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:0TWM2OD1yLkG4PFgyKM7:TR?= MoHuV2FPT0WU
NCI-H727 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK5XXJKSzVyPUCuNVk4QTRizszN MU\TRW5ITVJ?
LCLC-97TM1 M4W0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PGWWlEPTB;MD6yNFk2PSEQvF2= MUXTRW5ITVJ?
NCI-H650 M1qzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS1b3BUUUN3ME2wMlIyOzh2IN88US=> MUfTRW5ITVJ?
NCI-H2122 NVLIXFRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LZT2lEPTB;MD6yN|I6QSEQvF2= M17Pe3NCVkeHUh?=
SK-N-DZ NWTlbHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITLNIlKSzVyPUCuNlM3QThizszN M4PYfHNCVkeHUh?=
HT-29 NVWxTpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHOTWM2OD1yLkK0NlQ5KM7:TR?= MYrTRW5ITVJ?
LB771-HNC NGT5TGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTJOXZzUUN3ME2wMlI2QTF3IN88US=> NETDSYFUSU6JRWK=
HT-144 NGPwO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvzb2puUUN3ME2wMlI3OTlzIN88US=> NIPGNJdUSU6JRWK=
LAN-6 M2e3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfSWW9KSzVyPUCuNlY{PDhizszN NHzERlRUSU6JRWK=
EW-18 NFzqXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPaTWM2OD1yLkK3NFAyKM7:TR?= NHnI[YhUSU6JRWK=
LS-1034 M{PKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\scYR7UUN3ME2wMlI4OTN{IN88US=> Mn\wV2FPT0WU
EW-11 NXrGdoNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO3XHhRUUN3ME2wMlI5PDN{IN88US=> MmXPV2FPT0WU
SNU-C1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMkmzNVMh|ryP NWrNUWJOW0GQR1XS
RS4-11 NWjTXXo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTVTWM2OD1yLkOzO|U5KM7:TR?= MUPTRW5ITVJ?
ES4 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXPW49mUUN3ME2wMlQyODN6IN88US=> MmS4V2FPT0WU
COLO-320-HSR MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX4fYhKSzVyPUCuOFE{PjhizszN M4C3S3NCVkeHUh?=
NB10 M4D4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwNEW0N|ch|ryP Mo\UV2FPT0WU
BFTC-905 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HLNmlEPTB;MD60Olc2QCEQvF2= MUDTRW5ITVJ?
A375 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn61TWM2OD1yLkS3OlE4KM7:TR?= MlTjV2FPT0WU
SJRH30 M{W2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3kR49jUUN3ME2wMlUxQDJ{IN88US=> NGf5PGVUSU6JRWK=
NOS-1 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLRNnRPUUN3ME2wMlUzOjZ5IN88US=> MUjTRW5ITVJ?
SIG-M5 NE\nemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwNUO1OVch|ryP MlLXV2FPT0WU
DOK M4DPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrzU|hKSzVyPUCuOVU3KM7:TR?= NX3IPJcxW0GQR1XS
NB69 NX;wbnE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNUiyOVch|ryP MVPTRW5ITVJ?
SK-NEP-1 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\6cG1KSzVyPUCuOlAzOzZizszN MUnTRW5ITVJ?
SK-MM-2 M3L6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnBTWM2OD1yLk[1OFkyKM7:TR?= NX;mN|JlW0GQR1XS
NCI-H358 NYPsNIVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwNkewPFIh|ryP NWX2boJpW0GQR1XS
RH-1 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwN{S4OVkh|ryP M4fCfnNCVkeHUh?=
NH-12 NHHqNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHPdlN2UUN3ME2wMlc3ODR4IN88US=> M172V3NCVkeHUh?=
TE-12 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnnT|Y5UUN3ME2wMlc3PDh4IN88US=> NV\VSpMzW0GQR1XS
COLO-668 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O0WWlEPTB;MD64OFY3PiEQvF2= NWPCcmlVW0GQR1XS
PANC-08-13 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO0cmVKSzVyPUCuPFY{PzdizszN MYHTRW5ITVJ?
HCC2998 NULFb|FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwOEiyOlMh|ryP Mm\hV2FPT0WU
ABC-1 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrIeIxKSzVyPUCuPVA{PTJizszN MV;TRW5ITVJ?
ES6 M2HGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrLTWM2OD1yLkmxNFY3KM7:TR?= MUDTRW5ITVJ?
SNU-387 NILPU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwOUmzPVMh|ryP MlXMV2FPT0WU
CMK MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH3TWM2OD1yLkm5PVI6KM7:TR?= NGDSXYlUSU6JRWK=
SJSA-1 NGn2TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwMEO2OVMh|ryP Mke5V2FPT0WU
SIMA M4\TN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwME[4NlUh|ryP M2mzXHNCVkeHUh?=
ES3 NVzVe4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHITWM2OD1zLkGyNlk4KM7:TR?= MVzTRW5ITVJ?
IGROV-1 M2TncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj4dplKSzVyPUGuNVU1PDRizszN Ml;qV2FPT0WU
MEL-JUSO M3;PUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwMUW3OVkh|ryP MUnTRW5ITVJ?
T84 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlN4pKSzVyPUGuNlA6OTRizszN M4r0cHNCVkeHUh?=
CAL-85-1 M2nUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTGU2FKSzVyPUGuNlMyOzhizszN M{TEcXNCVkeHUh?=
RD NVTxb5dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHTSmJKSzVyPUGuNlY1PTVizszN MlHCV2FPT0WU
TE-8 NI\vd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwM{G0OlIh|ryP NHjVN2hUSU6JRWK=
L-363 NUK5[oxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPrTWM2OD1zLkO0NlA5KM7:TR?= M3\zcHNCVkeHUh?=
EKVX M2HZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\2SmlEPTB;MT6zOFU3QCEQvF2= MoDxV2FPT0WU
SK-MEL-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTMTWM2OD1zLkS4OVU3KM7:TR?= NGLI[5hUSU6JRWK=
TGBC24TKB NHLqfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LYR2lEPTB;MT61NFE6OyEQvF2= M2K1U3NCVkeHUh?=
NCI-H1770 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\vfHlkUUN3ME2xMlUyOTF|IN88US=> MkXJV2FPT0WU
HuH-7 NEfQWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkniTWM2OD1zLk[wNFk5KM7:TR?= NF\pfoVUSU6JRWK=
HL-60 M1Owe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwNk[5Nlgh|ryP MYXTRW5ITVJ?
TE-1 M{fCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXHWJJuUUN3ME2xMlcxQTR3IN88US=> MYLTRW5ITVJ?
LC-2-ad NV7XXoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXZ[HNKSzVyPUGuO|M5QDdizszN MVfTRW5ITVJ?
LB647-SCLC NIfr[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXiTWM2OD1zLke2OVg{KM7:TR?= MnrzV2FPT0WU
NCI-H2171 NVnWO5FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2elhJUUN3ME2xMlc4PzF4IN88US=> M{f4SXNCVkeHUh?=
SK-PN-DW M2TJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LOXGlEPTB;MT65NVI6QCEQvF2= NYrrXYJkW0GQR1XS
MC-IXC M3HKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD1zLkm4PVgh|ryP Mom4V2FPT0WU
LS-513 NEnRWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\3UJlKSzVyPUKuNFU{ODVizszN MW\TRW5ITVJ?
EW-3 NF[3WmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP0bnVFUUN3ME2yMlA6QDR2IN88US=> MkTuV2FPT0WU
OPM-2 NU[yXmM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrNZ204UUN3ME2yMlExOiEQvF2= MWHTRW5ITVJ?
LP-1 NFnRSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LvcmlEPTB;Mj6yOVgxPyEQvF2= M{Xqb3NCVkeHUh?=
LU-134-A Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13CVmlEPTB;Mj6yO|ch|ryP NXXmO2x{W0GQR1XS
CP66-MEL MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfhTWM2OD1{LkK5NFE1KM7:TR?= MkTyV2FPT0WU
HCC1143 NUDkc3dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXEd2czUUN3ME2yMlQ2OzZ6IN88US=> MWDTRW5ITVJ?
LOXIMVI NFLhNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXkTWM2OD1{Lk[wNlEh|ryP MWrTRW5ITVJ?
TE-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvEcYlKSzVyPUKuO|A5OzhizszN MVXTRW5ITVJ?
NCI-H1882 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwN{WyNlch|ryP NVzMcI5{W0GQR1XS
CHP-126 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y2WmlEPTB;Mj63OlMyPyEQvF2= M4DnbHNCVkeHUh?=
NCI-H1623 M3vxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfiNpdKSzVyPUKuPVIxOjRizszN NVvublIyW0GQR1XS
GB-1 NXPuZmVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGwephjUUN3ME2yMlk{PDB2IN88US=> NVj2PGR3W0GQR1XS
RCC10RGB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPMbGxKSzVyPUKuPVUzQDFizszN NH7XO2xUSU6JRWK=
NCI-H2141 M4LtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzpTJRXUUN3ME2yMlk3QDl4IN88US=> NInWOVJUSU6JRWK=
GI-ME-N MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPSWVYxUUN3ME2zMlAxPTZ3IN88US=> MX3TRW5ITVJ?
NCI-H526 NH\CPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r3bmlEPTB;Mz6wOFA5PSEQvF2= NYCxd|JzW0GQR1XS
NCI-H747 M1HJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHncHlKSzVyPUOuNFQ6QTJizszN MWDTRW5ITVJ?
SNU-423 M1\aUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwMkCzNVMh|ryP M2fDT3NCVkeHUh?=
A427 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLZeWhCUUN3ME2zMlI2Pjl7IN88US=> NYTtSVJTW0GQR1XS
CAL-12T NWfYNWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3zTmRKSzVyPUOuOFA4OTNizszN M1jPfHNCVkeHUh?=
LU-99A NGLmVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNwNEexNFUh|ryP MYDTRW5ITVJ?
MS-1 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf6eYRKSzVyPUOuOVM1OjlizszN MYrTRW5ITVJ?
SK-LU-1 NIrIbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjxfIJKSzVyPUOuO|YzQTVizszN MXTTRW5ITVJ?
SW837 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTJVnZiUUN3ME2zMlc3OzN|IN88US=> NEHybVdUSU6JRWK=
ES8 NULuSFcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v4S2lEPTB;Mz64N|g4PyEQvF2= NGGyNXJUSU6JRWK=
MZ2-MEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD3TWM2OD1|LkmyNFg3KM7:TR?= MkTsV2FPT0WU
TGW MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTRwMEGzNVEh|ryP NYjpRnBXW0GQR1XS
GP5d NEnlWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjXTGN6UUN3ME20MlA2OzZ{IN88US=> NFXJd|hUSU6JRWK=
BB49-HNC NYe0PVlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTRwMUWyNVMh|ryP M3PxVXNCVkeHUh?=
NB13 NFTqVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLIfYtrUUN3ME20MlI3QDh5IN88US=> MmfHV2FPT0WU
NTERA-S-cl-D1 M4HCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwMki2NVUh|ryP NU\qR3FUW0GQR1XS
NCI-H1648 NV6zPHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LSbWlEPTB;ND6yPVgyQSEQvF2= MmC0V2FPT0WU
LCLC-103H MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTTOo5lUUN3ME20MlMzOTl3IN88US=> MUHTRW5ITVJ?
LS-411N NIDXVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;OO2QyUUN3ME20MlQ1QDh3IN88US=> M1HldXNCVkeHUh?=
NCI-H1092 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq2VndkUUN3ME20MlQ2Pjh5IN88US=> MWPTRW5ITVJ?
PANC-10-05 NUTBPVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\jfWlEPTB;ND62PVg1KM7:TR?= MoH2V2FPT0WU
DK-MG M{C2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTRwOEC5N|Mh|ryP NH\Je5pUSU6JRWK=
OVCAR-5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dj[GlEPTB;ND64NVIzPiEQvF2= NEL4fZlUSU6JRWK=
CAL-39 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRwOEe2O{DPxE1? MnyzV2FPT0WU
TE-441-T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXMOllpUUN3ME20MlkxPTN5IN88US=> NHP2[mZUSU6JRWK=
MOLT-16 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr3TWM2OD12Lkm1NlU{KM7:TR?= M2r3XHNCVkeHUh?=
MCF7 NVTqW5F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHOTWM2OD13LkG0OVE4KM7:TR?= MnX4V2FPT0WU
CAPAN-1 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLSVppvUUN3ME21MlI2PzB5IN88US=> Mn3rV2FPT0WU
PSN1 NE\ZN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2OWdKSzVyPUWuNlczOzVizszN M{G3eXNCVkeHUh?=
NCI-H292 NFnDS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS5TWM2OD13LkOwNFQ1KM7:TR?= M2HjUnNCVkeHUh?=
CPC-N NWqxeXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX2O|lKSzVyPUWuN|k1OTlizszN Mki0V2FPT0WU
DoTc2-4510 NULNS4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTVwNEWzO|Eh|ryP Mo\QV2FPT0WU
LB1047-RCC Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqzTWM2OD13LkW1PVM{KM7:TR?= MlLPV2FPT0WU
MHH-ES-1 NHfWPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjHTWM2OD13LkW5PVA4KM7:TR?= MlfFV2FPT0WU
NMC-G1 NVjvZlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTVwN{CyNlch|ryP M2fKZnNCVkeHUh?=
SW1710 NHru[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H2cmlEPTB;NT63OFc2OSEQvF2= M{H4UnNCVkeHUh?=
YAPC NUfIXVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17lOGlEPTB;NT63OlIxOSEQvF2= NF7POlZUSU6JRWK=
22RV1 M2S2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j3emlEPTB;NT64NFAyQSEQvF2= NX7hdHBJW0GQR1XS
COLO-679 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\MWJJKSzVyPUWuPFg6PDhizszN M3LGSHNCVkeHUh?=
TCCSUP Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6zTWM2OD13LkmzNlU6KM7:TR?= Mmr0V2FPT0WU
C2BBe1 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi0N3FRUUN3ME21Mlk{QTdizszN NIH2cFNUSU6JRWK=
TE-15 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXN[XVKSzVyPU[uNFY3ODVizszN NXH4SllPW0GQR1XS
SCLC-21H NWniTHU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvOR2pKSzVyPU[uNVA5PDNizszN NX2z[JpDW0GQR1XS
EoL-1-cell MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITaOJRKSzVyPU[uNVY2PjNizszN M37PNXNCVkeHUh?=
NKM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXkdYFyUUN3ME22MlE3PzFizszN MV7TRW5ITVJ?
NCI-H1304 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf6TWM2OD14LkK3OFI5KM7:TR?= MUXTRW5ITVJ?
NB6 M4L4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7qTWM2OD14LkK5OlIzKM7:TR?= NHzKS2ZUSU6JRWK=
NALM-6 M3fvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHXVGdKSzVyPU[uN|MzOyEQvF2= MVjTRW5ITVJ?
NCI-H522 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjHVFVKSzVyPU[uN|M{ODZizszN NHnrS|NUSU6JRWK=
MV-4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1THOmlEPTB;Nj6zO|A4QSEQvF2= MV;TRW5ITVJ?
LB2241-RCC Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfSTWM2OD14LkO4OlY4KM7:TR?= NEfmN2hUSU6JRWK=
NCI-H1417 M3j2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrrTWM2OD14LkSwPFQ4KM7:TR?= NVTaR|dyW0GQR1XS
HT-1197 NWLGTlF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqwTWM2OD14LkW3NVIzKM7:TR?= NV;NdFJQW0GQR1XS
P30-OHK MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7vcmJwUUN3ME22MlYzPzdizszN NILSOI1USU6JRWK=
ALL-PO MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW0doJiUUN3ME22MlcyQTF4IN88US=> M3uxbXNCVkeHUh?=
OVCAR-4 NELPfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\1dWlEPTB;Nj63OVQxPSEQvF2= MYHTRW5ITVJ?
HCC2157 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mwWmlEPTB;Nj63O|Q4PSEQvF2= MkfiV2FPT0WU
NCI-H838 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\VdWV3UUN3ME22Mlk3PDlizszN NGKzNGpUSU6JRWK=
NCI-H1299 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTCXHNSUUN3ME22Mlk4ODlizszN M2rIOnNCVkeHUh?=
SW954 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTFW5A6UUN3ME23MlIxODZ6IN88US=> M{\RdHNCVkeHUh?=
NCI-H441 NXPUTJh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f3cWlEPTB;Nz6zOFA3PSEQvF2= NVnhXJVYW0GQR1XS
SK-MEL-2 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTdwNEizO|Mh|ryP MX;TRW5ITVJ?
KARPAS-45 NFnteIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrLTWM2OD15Lk[1PVI6KM7:TR?= NYriblZsW0GQR1XS
CAL-54 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknpTWM2OD15LkiyPVc4KM7:TR?= NH\0[pFUSU6JRWK=
KYSE-180 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrSNZRKSzVyPUeuPFg6PDFizszN NE\OSXZUSU6JRWK=
NCI-H187 M{\WVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXsTWM2OD15Lkm1PVQ4KM7:TR?= MojpV2FPT0WU
RT-112 M2jrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW4TWM2OD16LkC5Olc4KM7:TR?= MnfkV2FPT0WU
NCI-H1437 M122WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRThwMEm3PVUh|ryP NXTxSmZoW0GQR1XS
SNU-449 NHrLclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXzTWM2OD16LkK4NlczKM7:TR?= NF3ZeW9USU6JRWK=
HCC1187 M1XQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi5SmVjUUN3ME24MlI6OzlzIN88US=> NHvvZpJUSU6JRWK=
NCI-H2030 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwM{e3NVQh|ryP MV7TRW5ITVJ?
HuO-3N1 NFn1emlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVexUWxyUUN3ME24MlM4QDR2IN88US=> MnW5V2FPT0WU
COLO-792 NYfsOHo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:4TWM2OD16LkSxOVI4KM7:TR?= Ml;XV2FPT0WU
MIA-PaCa-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;rV2lEPTB;OD64OVUxQCEQvF2= NXT5Uo0{W0GQR1XS
SK-N-FI MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jQeWlEPTB;OT6wOFI2KM7:TR?= MXHTRW5ITVJ?
MMAC-SF NHvsTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jJSWlEPTB;OT6wPVc2OSEQvF2= Mn\lV2FPT0WU
NCI-H28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTlwMUC0Olkh|ryP NG\JOZNUSU6JRWK=
ETK-1 NV\XWXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[0TY5bUUN3ME25MlI6QTd2IN88US=> NHrrRXdUSU6JRWK=
NCI-H1993 NIDwTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CyTWlEPTB;OT60OFI3OSEQvF2= NUDaXpZlW0GQR1XS
no-11 NIe3UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\wZ2lEPTB;OT60O|EzKM7:TR?= NELsOVJUSU6JRWK=
ChaGo-K-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXtTWM2OD17LkWxOVg{KM7:TR?= NEC2bWVUSU6JRWK=
NCCIT MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXmTWM2OD17LkWzNVY6KM7:TR?= Ml;LV2FPT0WU
SAS NXjGbWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELmW5hKSzVyPUGwMlI1QCEQvF2= NGX4WIJUSU6JRWK=
A673 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nTdmlEPTB;MUCuN|cxPCEQvF2= MXHTRW5ITVJ?
NCI-H1522 M{SxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPDfIFKSzVyPUGwMlM4ODdizszN Ml;EV2FPT0WU
NCI-H810 M1fh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\1SGlEPTB;MUCuN|kxPyEQvF2= NHG1TlBUSU6JRWK=
IST-MES1 M{C5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Plc2lEPTB;MUCuOFU3PCEQvF2= NIHoUlZUSU6JRWK=
GR-ST NIjEZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\nZmlEPTB;MUCuOVAzPCEQvF2= M2XKbnNCVkeHUh?=
SUP-T1 NXnMT|dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rXS2lEPTB;MUCuO|MyPyEQvF2= MWLTRW5ITVJ?
NB5 NXfUWYVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFyLkmwNlIh|ryP M1zYSXNCVkeHUh?=
MZ1-PC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnleldKSzVyPUGwMlk2PzFizszN MljZV2FPT0WU
SK-CO-1 M1j2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnVc41KSzVyPUGwMlk6OzFizszN M{\aSXNCVkeHUh?=
Capan-2 M4Tqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HIeGlEPTB;MUGuN|E6QCEQvF2= M2DzPXNCVkeHUh?=
697 NVT5eJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK0TGx4UUN3ME2xNU43PzV5IN88US=> MU\TRW5ITVJ?
REH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD0TWM2OD1zMT63OFUyKM7:TR?= MYDTRW5ITVJ?
GI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[xRWlEPTB;MUGuPFYyPSEQvF2= NGK1[mpUSU6JRWK=
BB65-RCC NHzSeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDWVm1KSzVyPUGyMlA6OTZizszN M336W3NCVkeHUh?=
NCI-H1651 NUfh[FZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q2Z2lEPTB;MUKuNlQ4QCEQvF2= MWHTRW5ITVJ?
NCI-H1618 NInITHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF{LkO5O|Yh|ryP NUDTdXduW0GQR1XS
NCI-H2081 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnzWVdoUUN3ME2xNk43OTRzIN88US=> MYXTRW5ITVJ?
GCIY Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7rTWM2OD1zMj63NlE{KM7:TR?= MWHTRW5ITVJ?
NY M{HWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnkTWM2OD1zMz6wOlQ{KM7:TR?= NWPWcXdIW0GQR1XS
PANC-03-27 NGXZW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfqWXRtUUN3ME2xN{4xQDB5IN88US=> MUXTRW5ITVJ?
BHY NYj2OXkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7oXZdKSzVyPUGzMlIyOjFizszN NX;iXodnW0GQR1XS
SK-OV-3 NEj0OY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPzd3JKSzVyPUGzMlM4PjNizszN NXS4bGRIW0GQR1XS
5637 M1G4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\Bb2lEPTB;MUOuO|c2QSEQvF2= MV7TRW5ITVJ?
LC-1F MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy2SnJVUUN3ME2xOE4xOzV4IN88US=> M13j[XNCVkeHUh?=
SNB75 NIPGcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fTSWlEPTB;MUSuNFM5OyEQvF2= NWT2VXlUW0GQR1XS
CHP-212 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zJ[GlEPTB;MUSuNFQ3PCEQvF2= NETrOphUSU6JRWK=
HT-1376 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrHOGZKSzVyPUG0MlEyOjZizszN NVvRWlc2W0GQR1XS
MONO-MAC-6 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF2LkG1NFIh|ryP MmDrV2FPT0WU
CA46 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF2LkG4Nlch|ryP M{\EXnNCVkeHUh?=
SCC-15 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7MZZBKSzVyPUG0MlU2QDNizszN MlfnV2FPT0WU
ATN-1 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXYTWM2OD1zND62OlI4KM7:TR?= NF\iV3VUSU6JRWK=
NCI-H2405 NV7L[VR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF2LkixOVch|ryP MUfTRW5ITVJ?
NCI-H716 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF2Lki0PVMh|ryP Mn\PV2FPT0WU
SW620 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrKTWM2OD1zND65NFE1KM7:TR?= MVnTRW5ITVJ?
NCI-H226 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q3cGlEPTB;MUSuPVA5PSEQvF2= NIfLcndUSU6JRWK=
SW962 M1PiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrhXHRCUUN3ME2xOE46PDN{IN88US=> MUTTRW5ITVJ?
KYSE-150 NFPafXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLhTWM2OD1zND65OVUh|ryP NXridW9FW0GQR1XS
OCUB-M M2LTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT5V5ltUUN3ME2xOE46QDh|IN88US=> MmezV2FPT0WU
ES7 NXfuV2kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXGTWM2OD1zNT6wPVg1KM7:TR?= NGK1b3VUSU6JRWK=
SW1463 NEP3WnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH1fXJKSzVyPUG1MlQzOjNizszN MV3TRW5ITVJ?
CAKI-1 NGLIWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\IfXZyUUN3ME2xOU42OzR4IN88US=> NFXwXlJUSU6JRWK=
MKN28 M3PPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIThSVFKSzVyPUG1MlU1PzlizszN MmTFV2FPT0WU
SW13 M3vNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXLdVhkUUN3ME2xOU43OThizszN NXzxVVZYW0GQR1XS
A3-KAW NFS0eFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHMTWM2OD1zNT65Olk4KM7:TR?= NWnHU|g6W0GQR1XS
LU-65 NVfa[mpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfsWnA6UUN3ME2xOU46PzZ6IN88US=> Mm\VV2FPT0WU
Calu-1 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7XU2JKSzVyPUG2MlA{PjhizszN NXjPXHprW0GQR1XS
ST486 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL5OpFsUUN3ME2xOk4xPDNzIN88US=> NVnRNZV6W0GQR1XS
BB30-HNC NXryTXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF4LkGyOFYh|ryP MXLTRW5ITVJ?
EGI-1 NFjoboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfwUldKSzVyPUG2MlQ1PiEQvF2= NUPPXlFkW0GQR1XS
SH-4 M3;5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m0fGlEPTB;MU[uOFc{OSEQvF2= M2XWfHNCVkeHUh?=
MN-60 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF5LkKyPVch|ryP M33XV3NCVkeHUh?=
MPP-89 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF5LkK0OVkh|ryP NHHxXoZUSU6JRWK=
A2780 NVLFd3czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv1RYJkUUN3ME2xO{41OTN7IN88US=> M1XyPHNCVkeHUh?=
Daoy NXHte4d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGxSXFKSzVyPUG3MlQ3QTVizszN NX;DdoFCW0GQR1XS
NCI-H2126 M1vKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF5LkS3O|Eh|ryP MXjTRW5ITVJ?
NCI-H1563 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK4TWM2OD1zNz60PVE4KM7:TR?= M1q0T3NCVkeHUh?=
8-MG-BA M33Xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRflRtUUN3ME2xO{43PjR6IN88US=> M1fGTHNCVkeHUh?=
786-0 NUWyUGJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLpVVNPUUN3ME2xO{45OzV|IN88US=> MXHTRW5ITVJ?
AM-38 NW\aWIt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXDTGdJUUN3ME2xO{46OzB4IN88US=> M3u3d3NCVkeHUh?=
COLO-824 NVv1W5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\DSIxKSzVyPUG4MlQ1OzZizszN MmrUV2FPT0WU
SK-MEL-30 MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3rTWxKSzVyPUG4MlUxQDJizszN M2rUWHNCVkeHUh?=
CESS M4LCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF6Lke2NFkh|ryP MWjTRW5ITVJ?
BL-70 NGLicmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\IcmlEPTB;MUiuPFE2PiEQvF2= MVXTRW5ITVJ?
NCI-H2170 NFW5SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF6LkmxO|kh|ryP MWPTRW5ITVJ?
HT-3 M{HmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF6Lkm4N{DPxE1? M3jsUXNCVkeHUh?=
BOKU NEDrUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF7LkCzPFEh|ryP MV3TRW5ITVJ?
HPAF-II NEfvcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojmTWM2OD1zOT6zNFE2KM7:TR?= MVzTRW5ITVJ?
KGN M3H5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyw[ZBKSzVyPUG5MlQ4PjVizszN NXHGe45tW0GQR1XS
MC-CAR NYG1Z25RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Tz[2lEPTB;MUmuOlMyOyEQvF2= Moq4V2FPT0WU
BHT-101 M1fyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTOTWM2OD1zOT63O|ch|ryP MkfPV2FPT0WU
SW1783 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofDTWM2OD1zOT63PFA3KM7:TR?= NFXleY5USU6JRWK=
KP-N-YN M4nuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jVfmlEPTB;MkCuNFI3OiEQvF2= M3Ts[HNCVkeHUh?=
LU-165 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv2PIE4UUN3ME2yNE42PTdzIN88US=> Mle0V2FPT0WU
GOTO MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPxSXB5UUN3ME2yNE43PDVzIN88US=> NXO3N3EyW0GQR1XS
EFM-19 NV;tVpNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP6TWM2OD1{MT6wO|E3KM7:TR?= NVfadFhYW0GQR1XS
CTV-1 M{K4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHY[2ZKSzVyPUKxMlExPTRizszN NHvyPZhUSU6JRWK=
HEL M2\tdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LQe2lEPTB;MkGuOFIyPiEQvF2= M4TkfXNCVkeHUh?=
SNU-C2B MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG5dnZKSzVyPUKxMlQzPiEQvF2= Mlf0V2FPT0WU
ECC4 NHPSV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPmfllOUUN3ME2yNU44ODdizszN Mo\JV2FPT0WU
NEC8 NFj6NYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yxXWlEPTB;MkGuPFM3QCEQvF2= Mor3V2FPT0WU
KMOE-2 NUfn[2J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\PZnlKSzVyPUKxMlg6OjFizszN MnPmV2FPT0WU
NCI-H524 NXXzZVZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\P[mlEPTB;MkKuNFgxQCEQvF2= M33MSXNCVkeHUh?=
WSU-NHL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jHNmlEPTB;MkKuNVU4PyEQvF2= MYLTRW5ITVJ?
SF126 M2jVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjWd2JJUUN3ME2yNk4zPDZ7IN88US=> MlnCV2FPT0WU
HOP-92 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\5TWM2OD1{Mj6zNVY4KM7:TR?= Ml\1V2FPT0WU
CTB-1 NYCwSZIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXmVFY3UUN3ME2yNk41Pjd5IN88US=> NHjqVWtUSU6JRWK=
KYSE-270 M1nVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG0UGJKSzVyPUKyMlk{PTdizszN MmW3V2FPT0WU
SK-MEL-24 NIL2emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljMTWM2OD1{Mz6xPFch|ryP NEe4[3pUSU6JRWK=
Calu-3 NW[ycZVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\qTWM2OD1{Mz6yNVI5KM7:TR?= NFT4XVdUSU6JRWK=
GAMG NGnCbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDNTWM2OD1{Mz6yN|Y4KM7:TR?= MlnRV2FPT0WU
SW1573 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfObXN4UUN3ME2yN{44PDF3IN88US=> MkixV2FPT0WU
MHH-NB-11 M17GTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ2LkCxPVQh|ryP NWXmZlFRW0GQR1XS
TK10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zKbmlEPTB;MkSuOVAyOyEQvF2= MVfTRW5ITVJ?
LB373-MEL-D NX23Ro1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W0[WlEPTB;MkSuOlA3PCEQvF2= MVHTRW5ITVJ?
KALS-1 NIPqfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M170fmlEPTB;MkSuO|MzPyEQvF2= NXz6eFR2W0GQR1XS
HUTU-80 NYDzXHU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi0[2xDUUN3ME2yOU45ODN{IN88US=> MlfCV2FPT0WU
HuP-T3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPPRnpKSzVyPUK2MlE3PzRizszN MVPTRW5ITVJ?
OE19 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;5UYdKSzVyPUK2MlIyPTNizszN NVnCXIs5W0GQR1XS
J82 NGPROo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPiT2dKSzVyPUK2MlI1PzFizszN NH:xVVVUSU6JRWK=
DU-4475 M4XSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX4TWM2OD1{Nj6zPFE6KM7:TR?= MWrTRW5ITVJ?
DMS-53 M2\VRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjpNFd5UUN3ME2yOk42OTN6IN88US=> M1T4Z3NCVkeHUh?=
COLO-741 NHHkb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K4VGlEPTB;Mk[uPFM1PCEQvF2= MnLBV2FPT0WU
SW48 NVnwcWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonhTWM2OD1{Nj64PFIh|ryP NV74XYNNW0GQR1XS
IGR-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq0RoFKSzVyPUK2Mlk{OzRizszN NUPEV2dSW0GQR1XS
639-V M{X3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GzTWlEPTB;MkeuNFI1PSEQvF2= NIXMXW5USU6JRWK=
LK-2 M37tTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLrTWM2OD1{Nz60NVQyKM7:TR?= M4fmbHNCVkeHUh?=
NCI-H2347 NG[0PY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HLfmlEPTB;MkeuPVY6QSEQvF2= NWDBeFdWW0GQR1XS
NCI-H2228 NV7CSYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3RNppnUUN3ME2yPE4xQTB3IN88US=> MkH3V2FPT0WU
LS-123 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fNRmlEPTB;MkiuNVI3OiEQvF2= NXrl[XNrW0GQR1XS
U031 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ6LkK1NkDPxE1? MWTTRW5ITVJ?
NCI-H1792 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHITIVKSzVyPUK4MlQ4OjFizszN M{PsWHNCVkeHUh?=
NCI-H2087 M1nFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXlbHdIUUN3ME2yPE44PTV{IN88US=> M{\PUHNCVkeHUh?=
NCI-H2342 NVjtNYpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf0bo1KSzVyPUK5MlUzODhizszN NFW1[HRUSU6JRWK=
SW626 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXnTWM2OD1{OT63OVYh|ryP NGj2WINUSU6JRWK=
LB2518-MEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ7LkixOUDPxE1? M4j0NHNCVkeHUh?=
RXF393 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpTWM2OD1|MD6wPVUzKM7:TR?= NEXaRoFUSU6JRWK=
LC4-1 NHXKZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNyLkOwPVIh|ryP MlLBV2FPT0WU
NCI-H1694 NH;aZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNyLk[2NlQh|ryP NUXzbllDW0GQR1XS
K5 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNyLkm3NFIh|ryP NFzQSHBUSU6JRWK=
HDLM-2 NEPKcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n1RWlEPTB;M{CuPVczPSEQvF2= MnrMV2FPT0WU
BCPAP NXfKWFY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOxZmtKSzVyPUOxMlg{PzlizszN MWXTRW5ITVJ?
BC-3 NX3hWJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX0TWM2OD1|Mj6xOFA{KM7:TR?= NYflTVJbW0GQR1XS
LB996-RCC M2XmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jRcmlEPTB;M{KuNlM2QCEQvF2= MnryV2FPT0WU
NCI-H2009 NIDVWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PjNmlEPTB;M{KuOFk5OSEQvF2= NIjqOoZUSU6JRWK=
HTC-C3 M2j2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPnSVBKSzVyPUOzMlc2OTlizszN MmTtV2FPT0WU
LAMA-84 M4LzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\G[mlEPTB;M{SuOFQxPyEQvF2= Ml3HV2FPT0WU
CCRF-CEM MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnhU45xUUN3ME2zOE42PzF3IN88US=> M1fH[XNCVkeHUh?=
AN3-CA NHfnTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr6TJVKSzVyPUO1MlA2PjhizszN MWXTRW5ITVJ?
NCI-H1734 NF;KSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTN3LkK1OlEh|ryP NWLnbYdOW0GQR1XS
Ca-Ski MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT5XXR[UUN3ME2zOU41OTBzIN88US=> M4S4ZnNCVkeHUh?=
U-266 M133Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN3Lk[xNVQh|ryP MVPTRW5ITVJ?
SBC-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofHTWM2OD1|NT63O|gyKM7:TR?= MV7TRW5ITVJ?
GT3TKB MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN5LkGxOUDPxE1? M1rYT3NCVkeHUh?=
MDA-MB-175-VII MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TmbmlEPTB;M{euNlI1QCEQvF2= MXrTRW5ITVJ?
PFSK-1 M3joU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qxOmlEPTB;M{euNlQ{PSEQvF2= M3exTnNCVkeHUh?=
IMR-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7BTWM2OD1|Nz6yOFg4KM7:TR?= M2K5[HNCVkeHUh?=
Daudi NGSxVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fzNGlEPTB;M{euN|U6PyEQvF2= Mln0V2FPT0WU
A498 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN5LkeyNVgh|ryP NVXoNIIzW0GQR1XS
SCC-4 M4LZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHOPHpmUUN3ME2zO{44QDR|IN88US=> MXTTRW5ITVJ?
COLO-680N MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3mNG5PUUN3ME2zPE4zQDh3IN88US=> Mn3VV2FPT0WU
SK-MES-1 M3yybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOwfGZ{UUN3ME2zPE4{OjF3IN88US=> NYO1XZd4W0GQR1XS
SR NUC3Soc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHBTWM2OD1|OD61OFk2KM7:TR?= NYLaTWFlW0GQR1XS
LNCaP-Clone-FGC NIrjOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD3W5NKSzVyPUO4MlU3OzdizszN Mn\mV2FPT0WU
SK-HEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:5[GlEPTB;M{iuO|gzOiEQvF2= NHu4T2dUSU6JRWK=
BPH-1 NF3R[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rRfGlEPTB;M{iuPFMzQSEQvF2= MlHoV2FPT0WU
NCI-H1755 NYLoWnZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXSTWM2OD1|OT61PFE4KM7:TR?= MX7TRW5ITVJ?
LXF-289 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfYTWM2OD1|OT64NFg1KM7:TR?= NUSxSYhJW0GQR1XS
SW1088 M3vCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRyLkKxNFch|ryP MorBV2FPT0WU
MOLT-4 NH7pRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjwTWM2OD12MD6yPVAyKM7:TR?= Mof4V2FPT0WU
AsPC-1 NHPTVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRyLkS1PFMh|ryP NVKyS4lPW0GQR1XS
HOP-62 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4GxSGlEPTB;NECuOlU3QCEQvF2= NUnnZZd2W0GQR1XS
A172 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;HWFBKSzVyPUSwMlg2OTFizszN M2[5UnNCVkeHUh?=
SN12C NIPSOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL2[pVKSzVyPUSwMlk{QDVizszN NEjITWVUSU6JRWK=
MDA-MB-231 M4fLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7WTWM2OD12MD65PFk5KM7:TR?= NGjaRnVUSU6JRWK=
RPMI-2650 NYnFZ|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rtRmlEPTB;NEGuNVU6OyEQvF2= MnHmV2FPT0WU
KYSE-140 M{DvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn2WZlKSzVyPUSxMlgyOjNizszN Mn\1V2FPT0WU
KINGS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[wfm5KSzVyPUSyMlQ3QTdizszN NGTz[ZpUSU6JRWK=
HSC-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnk[JVvUUN3ME20Nk43PjZzIN88US=> MXnTRW5ITVJ?
PC-14 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jM[GlEPTB;NEOuNVg5OiEQvF2= M1nFOXNCVkeHUh?=
COR-L105 NVjCWmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zdYhMUUN3ME20N{43PTB{IN88US=> M37U[HNCVkeHUh?=
BE-13 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjWZYZNUUN3ME20OE4zOzdzIN88US=> NHzVVWVUSU6JRWK=
NCI-H661 M2DOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW3SpZOUUN3ME20OE4zQTV6IN88US=> NITQdHJUSU6JRWK=
IST-MEL1 M4HROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLpTWM2OD12ND6zOVk6KM7:TR?= MlywV2FPT0WU
HCC1806 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nTU2lEPTB;NESuOVg4OyEQvF2= NGLj[41USU6JRWK=
COLO-800 NXfPblR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jab2lEPTB;NESuPFQ2OyEQvF2= MV7TRW5ITVJ?
IST-SL2 NEXxXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHUWZlKSzVyPUS1MlEzPDdizszN M3X2[nNCVkeHUh?=
8305C Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR3LkOwPUDPxE1? NYfDeWhTW0GQR1XS
UACC-62 NHLCdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M370WGlEPTB;NE[uNlg4PSEQvF2= Mkm4V2FPT0WU
COR-L23 M1v0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TPZ2lEPTB;NEeuNVk6KM7:TR?= Ml\DV2FPT0WU
EFE-184 M2\IZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTR5LkO4PEDPxE1? NHuwclhUSU6JRWK=
DMS-114 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnFTWM2OD12Nz60NVQ6KM7:TR?= MlKzV2FPT0WU
KYSE-520 NGr0fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnviTWM2OD12OD61N|E2KM7:TR?= MkSxV2FPT0WU
SNG-M Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTR7LkSzOEDPxE1? MnT1V2FPT0WU
A2058 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLPTWM2OD12OT60PFg2KM7:TR?= M3jnZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
臨床試験 OSI-906 is currently under a Phase III clinical trial in adrenocortical carcinoma (ACC).
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

細胞アッセイ: [1]

細胞株 MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
濃度 0.02-0.8 μM
反応時間 3 days
実験の流れ For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

動物実験: [1]

動物モデル IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
製剤 25 mM tartaric acid
投薬量 25 mg / kg and 75 mg / kg
投与方法 Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download OSI-906 (Linsitinib) SDF
分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

カスタマーフィードバック (3)


Click to enlarge
Rating
Source Cancer Res, 2013, 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck
Method Cell proliferation and growth assays
Cell Lines PFR3 cells
Concentrations 1 μM
Incubation Time
Results The IC50 of PFR3 cells for PF299804 was more than 100 fold lower with the combination of OSI-90 than with PF00299804 alone.

Click to enlarge
Rating
Source Cancer Res, 2011, 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck
Method [18 F]FDG –PET/ Western blot
Cell Lines MCF-7 cells/athymic mice
Concentrations 50 mg/kg/day
Incubation Time 6 weeks
Results mice without palpable tumors were randomized to treatment with vehicle or OSI-906. Six of 20 control mice (30%) developed tumors, whereas none of the 20 OSI-906–treated mice did (Fig. A). OSI-906 inhibited tumor growth compared with vehicle (Fig. B; P < 0.05). OSI-906–treated tumors exhibited markedly lower levels of phosphorylated IGF-IR, InsR, IRS-1, AKT, and S6 compared with vehicle controls (Fig. C). FDG uptake was significantly decreased 4 hours after a single dose of OSI-906 com-pared with baseline (Fig. D)

Click to enlarge
Rating
Source OSI-906 (Linsitinib) purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 1 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

文献中の引用 (15)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related IGF-1R 阻害剤

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.

  • BMS-536924

    BMS-536924は、ATP競争的IGF-IRとIR阻害剤で、IC50 がそれぞれ 100 nM と 73 nMです。

  • NVP-AEW541

    NVP-AEW541は、IGF-IRとInsRの二重阻害剤で、IC50 がそれぞれ 86 nM と 140 nMです。

  • NVP-ADW742

    NVP-ADW742は、0.17のμMのIC50によるIGF1R阻害剤です。

  • GSK1904529A

    GSK1904529Aは選択性阻害剤、(IGF-IR) と (IR)を抑制する時、 IC50が それぞれ27 nM と 25 nMになる.

  • BMS-754807

    BMS-754807は、IGF1R/IR家族キナーゼの強力で可逆的な阻害剤で、 IGF-1RIRMetTrkATrkBを妨げ、IC50 がそれぞれ 1.8 nM、1.7 nM、5.6 nM、7.4 nM 、 4.1 nMです。

    Features:Muti-inhibitor of the IGR-1R/IR family.

最近チェックしたアイテム

Tags: OSI-906 (Linsitinib)を買う | OSI-906 (Linsitinib)供給者 | OSI-906 (Linsitinib)を購入する | OSI-906 (Linsitinib)費用 | OSI-906 (Linsitinib)生産者 | オーダーOSI-906 (Linsitinib) | OSI-906 (Linsitinib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ